In the News: Aducanumab (Aduhelm)
The Carlat Psychiatry Report, Volume 19, Number 11&12, November 2021
Rehan Aziz, MD.
Associate professor of psychiatry and neurology, Rutgers Robert Wood Johnson Medical School.
Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.